Nautilus Biotechnology, Inc.
NAUT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.30 | -0.54 | 0.17 | -0.31 |
| FCF Yield | -29.08% | -14.50% | -21.46% | -9.49% |
| EV / EBITDA | -3.31 | -5.23 | -2.33 | -5.92 |
| Quality | ||||
| ROIC | -34.06% | -25.39% | -18.32% | -12.80% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.81 | 0.79 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -13.14% | -12.51% | -15.95% | -178.27% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | -0.20 | 1.40 | 3.26 |
| Interest Coverage | 0.00 | 0.00 | -10.94 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -56.71 | -104.86 | -135.91 | -221.29 |